NIH, industry and non-profits join forces to speed validation of disease targets

Tuesday, February 4, 2014

Goal is to develop new treatments earlier, beginning with Alzheimer’s, type 2 diabetes, and autoimmune disorders

The National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations today launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development. The Accelerating Medicines Partnership (AMP) aims to distinguish biological targets of disease most likely to respond to new therapies and characterize biological indicators of disease, known as biomarkers.